Diagnostics and genetic testing firm Prenetics Global has introduced an at-home blood test series, Circle Snapshot, featuring a CE-certified blood collection device.
The painless, push-button, micro-needle device has been designed to draw capillary blood painlessly with the help of a new microfluidic extraction process.
Circle Snapshot is intended to analyse blood samples across more than 50 areas of health concern, including heart health, vitamin deficiency, food intolerance, diabetes risk, food allergy, sexual health, and men’s and women’s health.
Prenetics stated that the at-home health test series will be introduced in phases.
The Heart Health, Food Sensitivity and Covid-19 Antibody Test series are currently being made available, with additional tests expected to be offered in the coming months.
Users can start the sample collection by pushing a button after placing the device on their upper arm. It takes less than two minutes to collect the sample.
The Heart Health test will measure total hs-CRP, LDL, non-HDL cholesterol, triglycerides, HDL, TC/LDL ratio and TG/HDL ratio.
The Covid-19 Antibody Test is designed to measure current antibody levels from 0 AU/mL to 40,000 AU/mL.
These levels help to identify whether a person has sufficient antibodies from previous vaccination and/or infection.
The Food Sensitivity Test is for a set of 96 foods that may cause discomforts, such as headache, bloating, indigestion and abdominal pain.
Prenetics CEO and co-founder Danny Yeung said: “With more importance being placed on health awareness due to Covid-19, at-home blood test has a significant opportunity to make preventive testing accessible and affordable.
“Many individuals just don’t have the time and/or afraid of needles to get blood tests, with Circle Snapshot, the convenience of being able to draw blood painlessly at-home or even at a restaurant is a game-changer.
“As such, we are delighted to launch Circle Snapshot, which will play a key role in helping the public discover their current health status across key areas of health.”
The company noted that the new at-home blood test will initially be launched in Hong Kong, followed by Southeast Asia and the UK.